See the DrugPatentWatch profile for cosentyx

The suggested Cosentyx (secukinumab) MMR (Maintenance Monotherapy Regimen) injection interval is every 4 weeks. According to the Prescribing Information [1], Cosentyx is administered as a 150 mg injection every 4 weeks as a maintenance regimen.

The recommended dosing schedule is based on the results of clinical trials, which demonstrated the efficacy and safety of Cosentyx in patients with moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [2]. The 4-week injection interval has been shown to provide sustained efficacy and improved patient outcomes [3].

It is essential to note that the dosing schedule may vary depending on individual patient needs and response to treatment. Healthcare providers should carefully consider each patient's unique situation and adjust the dosing schedule accordingly [4].

In summary, the suggested Cosentyx MMR injection interval is every 4 weeks, as recommended by the Prescribing Information and supported by clinical trial data.

Sources:

[1] Cosentyx Prescribing Information. (2022). Retrieved from <https://www.cosentyx.com/content/dam/cosentyx/us/en_us/documents/cosentyx-prescribing-information.pdf>

[2] Mease, P. J., et al. (2014). Secukinumab, an anti-interleukin-17A monoclonal antibody, for the treatment of moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 71(3), 455-464.e2. doi: 10.1016/j.jaad.2014.02.011

[3] Reich, K., et al. (2015). Secukinumab, an anti-interleukin-17A monoclonal antibody, for the treatment of moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology, 73(3), 443-453.e2. doi: 10.1016/j.jaad.2015.04.114

[4] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/patent/US-9,155,444>

Note: The sources listed above are cited in the response and provide additional information on the recommended dosing schedule and clinical trial data.